Pharmaceutical Market Europe • September 2026 • 20
THOUGHT LEADER
‘How do you prove that omnichannel is working and providing business value?’
By Ruzanna Martirosyan
Most pharma omnichannel programmes can tell leadership how many emails were opened. Very few can tell them whether any of it changed a behaviour, mindset or prescribing decision. That gap – between channel activity and business outcome – is the real barrier to sustained omnichannel investment.
Let’s start with the questions leadership and clients are always asking – how do you prove that omnichannel is working and providing business value? And is it worth all the effort and investment?
According to McKinsey’s 2026 analysis of pharma CX investment, 73% of pharma CX pilots fail to reach full deployment. In most cases the strategy was sound. The failure was that success was never properly defined and the measurement architecture to demonstrate it to leadership was never built.
Most pharma omnichannel programmes are measured against what I call vanity metrics: activity and engagement metrics, email open rates, page views, impressions, click throughs, rep call frequency, eDetailing completion rates, etc. These metrics are real, they are trackable, but they are almost entirely unconvincing to a Chief Commercial Officer making a resource allocation decision. The question leadership asks is not: ‘How many healthcare professionals (HCPs) opened the email?’ It is: ‘Did any of them change their prescribing behaviour?’ Engagement data cannot answer that question, which is why omnichannel programmes that report only on campaign metrics level consistently struggle to secure or expand investment.
Connecting omnichannel activity to commercial outcomes requires a three-tier framework:
Tier 1 – engagement quality
Not volume but relevance and depth: content consumption rate, channel preference accuracy for each HCP segment, next-best-action acceptance rate by the field force. The question is not how many interactions happened but whether they were the right interactions for the right HCP at the right moment.
Tier 2 – clinical behaviour signals
Changes in prescribing pattern in targeted segments, adoption speed, HCP-initiated contact following an omnichannel sequence, referral rate changes in supported patient populations. These signals exist in most pharma organisations. They are rarely connected to the omnichannel data that preceded them.
Tier 3 – commercial outcomes
Pipeline conversion rate, revenue per engaged HCP, market share movement in targeted specialties. Tier 3 is where the budget conversation happens. It is also where most omnichannel measurement frameworks fall short.
Connecting all three tiers requires more than better dashboards. It requires a governance function – what I call the Customer Experience Steward: a cross-functional role with authority spanning commercial, medical and tech, responsible for building and maintaining the single HCP view, owning the measurement framework and translating the data into a commercial narrative that leadership will act on.
This role does not widely exist in pharma commercial organisations, but it should. It falls between functions – commercial does not own medical data and IT does not own strategy. The result is a complete picture of omnichannel performance that no one has at the moment.
This is not just about measurement, but about demonstrating the business value of omnichannel and creating an opportunity to embed the omnichannel thinking into the business model, rather than view it as campaign activation.
Three things change when measurement architecture is built in from the start rather than bolted on at the end:
1. The budget conversation changes – leadership shifts from asking ‘what did the programme reach?’ to ‘what did the programme move?’
2. Channel orchestration improves – when one function has visibility across all channel data, the patterns that drive prescribing decisions become visible
3. Programme design improves – because it is designed around the outcomes it needs to demonstrate, not just the channels.
Where that Customer Experience Steward role doesn’t yet exist, Spectrum Science steps into it, connecting the tiers, building the measurement architecture and turning omnichannel activity into commercial momentum for your brand.
Get in touch to build your team’s momentum at www.spectrumscience.com/contact/
Ruzanna Martirosyan is Executive Director, Customer Experience & Emerging Tech, Spectrum Science